Aug 20, 2025 • Benzinga
NEUTRAL
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - Rhythm Pharmaceuticals ( NASDAQ:RYTM )
- U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- - European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity -
Aug 19, 2025 • Benzinga
NEUTRAL
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Eli Lilly ( NYSE:LLY )
Novo's pill requires ~75 times more active ingredient per week than Wegovy injections. Lilly has $808.5 million in orforglipron inventory ahead of its planned 2026 launch. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →
Aug 05, 2025 • Motley Fool
SOMEWHAT-BULLISH
Rhythm ( RYTM ) Q2 Revenue Jumps 67%
Rhythm Pharmaceuticals ( NASDAQ:RYTM ) , a biopharmaceutical company focused on rare genetic diseases related to obesity, reported its Q2 2025 earnings on August 5, 2025. However, the company reported a GAAP net loss per share of ( $0.75 ) .
Aug 05, 2025 • Zacks Commentary
NEUTRAL
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 30, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Exact Sciences ( EXAS ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jul 29, 2025 • Zacks Commentary
NEUTRAL
Earnings Preview: Rhythm Pharmaceuticals, Inc. ( RYTM ) Q2 Earnings Expected to Decline
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.